CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Eisai Co. Ltd. v. Mylan Pharmaceuticals Inc.

1:13-cv-01282

Overview

Case Number 1:13-cv-01282
Filing Date 2013-07-24
Status Terminated
Termination Date 2016-10-13
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Pharmaceuticals Inc. Operating Company

Represented By

7 Attorneys Listed

Richard L. Horwitz

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Tung-On Kong

Email: tkong@wsgr.com

S. Brei Gussack

Email: bgussack@wsgr.com

Elham F. Steiner

Email: esteiner@wsgr.com

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Plaintiff

Novartis Pharma AG Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Eisai Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Eisai Co. Ltd. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 6 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (6): πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6740669
Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Filed: 1998-06-08
Issued: 2004-05-25
Expired (Term Ended) +801d PTA
Expires: 2020-08-17
US7750028
Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
Filed: 2006-01-11
Issued: 2010-07-06
Expired (Term Ended)
Expires: 2018-10-19
US8076362
Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
Filed: 2010-04-26
Issued: 2011-12-13
Active (3.4 yrs remaining)
Expires: 2030-04-26

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+801 days) / Cellect Scrutiny β€” Over 801 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

5

Dispositive

0

Granted

0

Denied

0

Pending / Review

3

Motions by Category

Claim Construction / Markman Filing 1 Procedural / Extension Motion 4

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re (21 in 1:13-cv-01282-LPS, 24 in 1:13-cv-01280-LPS, 20 in 1:13-cv-01279-LPS, 23 in 1:13-cv-01284-LPS, 22 in 1:13-cv-01281-LPS) STIPULATION TO EXTE...
Entry #β€” • 2014-03-05
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Submit a Proposed Protective Order to March 10, 2014 - filed by Roxane Laboratories Inc., Hetero Labs Ltd., Hetero USA Inc., Mylan...
Entry #21 • 2014-03-03 Document →
Procedural / Extension Motion Pending
SO ORDERED, re (20 in 1:13-cv-01282-LPS, 23 in 1:13-cv-01280-LPS, 19 in 1:13-cv-01279-LPS, 21 in 1:13-cv-01281-LPS, 21 in 1:13-cv-01284-LPS) STIPULATION TO EXTE...
Entry #β€” • 2014-02-27
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for the parties to submit a proposed protective order to March 3, 2014 - filed by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (No...
Entry #20 • 2014-02-24 Document →
Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Discovery due by 1/23/2015. Status Report due by 10/3/2014. Claim Cons...
Entry #16 • 2014-01-23 Document →

Docket Entries

(47 total)
Pleading / Complaint

COMPLAINT - filed against Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1334548.) - filed by Eisai Inc., Eisai Co. Ltd., Novartis Pharma AG. (Attachments: # 1 Exhibits A-C, # 2 Civil Cover Sheet)(rwc) (Entered: 07/25/2013)

Entry #1 • 2013-07-24
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (rwc) (Entered: 07/25/2013)

Entry #2 • 2013-07-24
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 6/20/13. Date of Expiration of Patent: (See Form).Thirty Month Stay Deadline: 5/14/2016. (rwc) (Entered: 07/25/2013)

Entry #3 • 2013-07-24
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,740,669 B1; 7,750,028 B2; 8,076,362 B2. (rwc) (Entered: 07/25/2013)

Entry #4 • 2013-07-24
1

Disclosure Statement pursuant to Rule 7.1 filed by Eisai Co. Ltd., Eisai Inc. identifying Corporate Parent Eisai Corporation of North America, Corporate Parent Eisai Co. Ltd. for Eisai Inc.. (rwc) (Entered: 07/25/2013)

Entry #5 • 2013-07-24
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc